Skip to main content
SpringerLink
Log in

C1q and the glomerulonephritides: therapeutic approaches for the treatment of complement-mediated kidney diseases

  • Chapter
Complement and Kidney Disease

Part of the book series: Progress in Inflammation Research ((PIR))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jennette JC, Hipp CG (1985) C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis 6: 103–110

    CAS  PubMed  Google Scholar 

  2. Sharman A, Furness P, Feehally J (2004) Distinguishing C1q nephropathy from lupus nephritis. Nephrol Dial Transplant 19: 1420–1426

    CAS  PubMed  Google Scholar 

  3. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C et al (2004) Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 114: 679–688

    Article  CAS  PubMed  Google Scholar 

  4. Cochrane CG, Unanue ER, Dixon FJ (1965) A role of polymorphonuclear leukocytes and complement in nephrotoxic nephritis. J Exp Med 122: 99–116

    Article  CAS  PubMed  Google Scholar 

  5. Salant DJ, Belok S, Madaio MP, Couser WG (1980) A new role for complement in experimental membranous nephropathy in rats. J Clin Invest 66: 1339–1350

    CAS  PubMed  Google Scholar 

  6. Brandt J, Pippin J, Schulze M, Hansch GM, Alpers CE, Johnson RJ, Gordon K, Couser WG (1996) Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 49: 335–343

    CAS  PubMed  Google Scholar 

  7. Baker PJ, Ochi RF, Schulze M, Johnson RJ, Campbell C, Couser WG (1989) Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol 135: 185–194

    CAS  PubMed  Google Scholar 

  8. Nangaku M, Pippin J, Couser WG (1999) Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 10: 2323–2331

    CAS  PubMed  Google Scholar 

  9. Shah SV (1988) Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats. Am J Physiol 254: F337–F344

    CAS  PubMed  Google Scholar 

  10. Neale TJ, Ojha PP, Exner M, Poczewski H, Ruger B, Witztum JL, Davis P, Kerjaschki D (1994) Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J Clin Invest 94: 1577–1584

    CAS  PubMed  Google Scholar 

  11. Benzaquen LR, Nicholson-Weller A, Halperin JA (1994) Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179: 985–992

    Article  CAS  PubMed  Google Scholar 

  12. Couser WG, Pippin JW, Shankland SJ (2001) Complement (C5b-9) induces DNA synthesis in rat mesangial cells in vitro. Kidney Int 59: 905–912

    Article  CAS  PubMed  Google Scholar 

  13. Hsu SI and Couser WG (2003) Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 14: S186–S191

    Article  CAS  PubMed  Google Scholar 

  14. Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T (1998) Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 13: 1984–1990

    CAS  PubMed  Google Scholar 

  15. Roos A, Bouwman LH, Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR (2001) Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 167: 2861–2868

    CAS  PubMed  Google Scholar 

  16. Lhotta K, Wurzner R, Konig P (1999) Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant 14: 881–886

    CAS  PubMed  Google Scholar 

  17. Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22: 431–456

    Article  CAS  PubMed  Google Scholar 

  18. Botto M, Dell’Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19: 56–59

    CAS  PubMed  Google Scholar 

  19. Paul E, Pozdnyakova OO, Mitchell E, Carroll MC (2002) Anti-DNA autoreactivity in C4-deficient mice. Eur J Immunol 32: 2672–2679

    Article  CAS  PubMed  Google Scholar 

  20. Mitchell DA, Pickering MC, Warren J, Fossati-Jimack L, Cortes-Hernandez J, Cook HT, Botto M, Walport MJ (2002) C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 168: 2538–2543

    CAS  PubMed  Google Scholar 

  21. Nash JT, Taylor PR, Botto M, Norsworthy PJ, Davies KA, Walport MJ (2001) Immune complex processing in C1q-deficient mice. Clin Exp Immunol 123: 196–202

    Article  CAS  PubMed  Google Scholar 

  22. Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, Savill JS, Henson PM, Botto M, Walport MJ (2000) A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 192: 359–366

    Article  CAS  PubMed  Google Scholar 

  23. Roos A, Xu W, Castellano G, Nauta AJ, Garred P, Daha MR, van Kooten C (2004) Mini-review: A pivotal role for innate immunity in the clearance of apoptotic cells. Eur J Immunol 34: 921–929

    CAS  PubMed  Google Scholar 

  24. Nauta AJ, Castellano G, Xu W, Woltman AM, Borrias MC, Daha MR, van Kooten C, Roos A (2004) Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol 173: 3044–3050

    CAS  PubMed  Google Scholar 

  25. Casciola-Rosen LA, Anhalt G, Rosen A (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179: 1317–1330

    Article  CAS  PubMed  Google Scholar 

  26. Robson MG, Cook HT, Botto M, Taylor PR, Busso N, Salvi R, Pusey CD, Walport MJ, Davies KA (2001) Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol 166: 6820–6828

    CAS  PubMed  Google Scholar 

  27. Sheerin NS, Springall T, Abe K, Sacks SH (2001) Protection and injury: the differing roles of complement in the development of glomerular injury. Eur J Immunol 31: 1255–1260

    Article  CAS  PubMed  Google Scholar 

  28. Uwatoko S, Mannik M (1988) Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagenlike region of C1q. J Clin Invest 82: 816–824

    CAS  PubMed  Google Scholar 

  29. Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P, Testoni C, Tincani A, Banfi G, Balestrieri G et al (2001) Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37: 490–498

    CAS  PubMed  Google Scholar 

  30. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA (2005) Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 64: 444–448. Epub 2004 Jul 29

    CAS  PubMed  Google Scholar 

  31. Trendelenburg M, Marfurt J, Gerber I, Tyndall A, Schifferli JA (1999) Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 42: 187–188

    Article  CAS  PubMed  Google Scholar 

  32. Trouw LA, Seelen MA, Duijs JM, Benediktsson H, van Kooten C, Daha MR (2003) Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol 132: 32–39

    Article  CAS  PubMed  Google Scholar 

  33. Trouw LA, Duijs JM, van Kooten C, Daha MR (2003) Immune deposition of C1q and anti-C1q antibodies in the kidney is dependent on the presence of glomerular IgG. Mol Immunol 40: 595–602

    CAS  PubMed  Google Scholar 

  34. Trouw LA, Seelen MA, Visseren R, Duijs JM, Benediktsson H, de Heer E, Roos A, van Kooten C, Daha MR (2004) Anti-C1q autoantibodies in murine lupus nephritis. Clin Exp Immunol 135: 41–48

    Article  CAS  PubMed  Google Scholar 

  35. van den Berg RH, Faber-Krol MC, Sim RB, Daha MR (1998) The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol 161: 6924–6930

    PubMed  Google Scholar 

  36. Lozada C, Levin RI, Huie M, Hirschhorn R, Naime D, Whitlow M, Recht PA, Golden B, Cronstein BN (1995) Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules Eselectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci USA 92: 8378–8382

    CAS  PubMed  Google Scholar 

  37. Roos A, Ramwadhdoebe TH, Nauta AJ, Hack CE, Daha MR (2002) Therapeutic inhibition of the early phase of complement activation. Immunobiology 205: 595–609

    Article  CAS  PubMed  Google Scholar 

  38. Hoekzema R, Martens M, Brouwer MC, Hack CE (1988) The distortive mechanism for the activation of complement component C1 supported by studies with a monoclonal antibody against the “arms” of C1q. Mol Immunol 25: 485–494

    Article  CAS  PubMed  Google Scholar 

  39. Roos A, Nauta AJ, Broers D, Faber-Krol MC, Trouw LA, Drijfhout JW, Daha MR (2001) Specific inhibition of the classical complement pathway by C1q-binding peptides. J Immunol 167: 7052–7059

    CAS  PubMed  Google Scholar 

  40. Roos A, Ramwadhdoebe TH, Nauta AJ, Hack CE, Daha MR (2002) Therapeutic inhibition of the early phase of complement activation. Immunobiology 205: 595–609

    Article  CAS  PubMed  Google Scholar 

  41. Rieben R, Roos A, Muizert Y, Tinguely C, Gerritsen AF, Daha MR (1999) Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 93: 942–951

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, C3-P25, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands

    Stefan P. Berger, Tom W.L. Groeneveld, Anja Roos & Mohamed R. Daha

Authors
  1. Stefan P. Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tom W.L. Groeneveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anja Roos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohamed R. Daha
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knoell Institute, Beutenbergstr. 11a, D-07745, Jena, Germany

    Peter F. Zipfel

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Berger, S.P., Groeneveld, T.W., Roos, A., Daha, M.R. (2006). C1q and the glomerulonephritides: therapeutic approaches for the treatment of complement-mediated kidney diseases. In: Zipfel, P.F. (eds) Complement and Kidney Disease. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7428-4_3

Download citation

Publish with us

Policies and ethics

Search

Navigation